Blood Glucose Monitoring and Insulin Dose Adjustment for Patients on Basal Insulin
For patients with type 2 diabetes taking basal insulin, assess fasting blood glucose with self-monitoring to inform dose adjustments every 2-3 days until reaching target fasting glucose <110 mg/dL, with the specific titration based on fasting glucose levels: increase by 20% if >180 mg/dL, 10% if 140-180 mg/dL, and 1 unit if 110-139 mg/dL 1.
Monitoring Frequency
While evidence is insufficient regarding exact monitoring frequency for patients on basal insulin alone (not intensive regimens), assessing fasting glucose with self-monitoring of blood glucose (SMBG) is essential to inform dose adjustments and results in lower A1C 2, 3, 4.
The practical approach:
- Check fasting blood glucose regularly (at minimum, enough to guide titration every 2-3 days initially)
- Once stable, monitoring can be less frequent but should continue to ensure targets are maintained
- Consider continuous glucose monitoring (CGM) for enhanced monitoring of both hyperglycemia and hypoglycemia, particularly during initial titration phases 5
Insulin Dose Titration Algorithm
Initial Dosing
Start basal insulin based on A1C at initiation 1:
- A1C <8%: 0.1-0.2 units/kg/day
- A1C >8%: 0.2-0.3 units/kg/day
Titration Schedule
Titrate every 2-3 days to reach glycemic targets 1. For longer-acting insulins like degludec, slower titration every 3-5 days is recommended due to longer half-life.
Specific Adjustment Protocol
Based on fasting blood glucose 1:
For hyperglycemia:
- FBG >180 mg/dL: Increase by 20%
- FBG 140-180 mg/dL: Increase by 10%
- FBG 110-139 mg/dL: Increase by 1 unit
For hypoglycemia:
- FBG <70 mg/dL: Decrease by 10-20%
- FBG <40 mg/dL: Decrease by 20-40%
Target Goals
- Fasting blood glucose <110 mg/dL without hypoglycemia 1
- A1C ≤6.5% (individualized based on comorbidities and hypoglycemia risk) 1
Critical Pitfalls to Avoid
Overbasalization is a common error—continuing to escalate basal insulin doses beyond approximately 0.5 units/kg/day without meaningful reduction in fasting glucose 6, 7. When basal doses exceed this threshold or when the bedtime-to-morning glucose differential is high, re-evaluate therapy rather than continuing to increase basal insulin. Consider adding prandial insulin or GLP-1 receptor agonist instead 1.
Patient Education Requirements
Patients can be counseled to titrate insulin doses independently based on self-monitoring, using the algorithm above 1. This approach has been validated—glucose readings alone are sufficient for effective dose adjustments when titration occurs every 1-4 weeks 8.
All patients and their families must be educated on:
- Symptoms and treatment of hypoglycemia (<70 mg/dL) and severe hypoglycemia (<54 mg/dL)
- Oral glucose sources (tablets, fruit juice) for conscious patients
- Glucagon administration for unresponsive patients 1
Insulin Selection Considerations
Analog insulins (detemir, glargine, degludec) are preferred over NPH to reduce hypoglycemia risk 1. Longer-acting analogs (glargine U-300, degludec) provide lower nocturnal hypoglycemia risk compared to glargine U-100 6.
When to Intensify Beyond Basal Insulin
If glycemic targets are not met with basal insulin optimization, consider fixed-dose GLP-1 RA/basal insulin combinations before adding prandial insulin to minimize hypoglycemia and weight gain risks 1, 6. If prandial insulin becomes necessary, add stepwise to 1-3 meals starting with the largest meal 1.